Uniqueness of lung cancer in Southeast Asia.

Lung cancer varies between Caucasians and Asians. There have been differences recorded in the epidemiology, genomics, standard therapies and outcomes, with variations according to the geography and ethnicity which affect the decision for optimal treatment of the patients. To better understand the profile of lung cancer in Southeast Asia, with a focus on India, we have comprehensively reviewed the available data, and discuss the challenges and the way forward. A substantial proportion of patients with lung cancer in Southeast Asia are neversmokers, and adenocarcinoma is the common histopathologic subtype, found in approximately a third of the patients. EGFR mutations are noted in 23-30% of patients, and ALK rearrangements are noted in 5-7%. Therapies are similar to global standards, although access to newer modalities and molecules is a challenge. Collaborative research, political will with various policy changes and patient advocacy are urgently needed.
Competing Interests: Dr. Vanita Noronha has received institutional research funding from AstraZeneca Pharma India Ltd, Glenmark, Nanobiotix SA, Novartis, and Roche Products (India) Pvt. Ltd. All research grants have been paid to the institution. Dr. Kumar Prabhash has received institutional research funding from Pfizer, Roche Products (India) Pvt. Ltd., and Alkem. All research grants have been paid to the institution.
(© 2024 The Authors.)